An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pulse Biosciences, Inc. (PLSE) announced it will release its first quarter 2024 financial results on May 7, 2024. The company will host a conference call for investors to discuss the results and provide insights into its CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology.
Pulse Biosciences, Inc. (PLSE) ha annunciato che pubblicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024. La compagnia terrà una conferenza telefonica per gli investitori per discutere i risultati e fornire dettagli sulla sua tecnologia di ablazione a campo pulsato nanosecondale CellFX® (nsPFA™).
Pulse Biosciences, Inc. (PLSE) anunció que publicará los resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La empresa organizará una llamada de conferencia para inversores para discutir los resultados y proporcionar información sobre su tecnología de ablación por campos pulsados de nanosegundos CellFX® (nsPFA™).
Pulse Biosciences, Inc. (PLSE)는 2024년 1분기 재무 결과를 2024년 5월 7일에 발표할 것이라고 발표했습니다. 회사는 투자자들과 결과를 논의하고 CellFX® 나노초 펄스 필드 절제술(nsPFA™) 기술에 대한 통찰을 제공하기 위한 회의 전화를 주최할 것입니다.
Pulse Biosciences, Inc. (PLSE) a annoncé qu'elle publiera ses résultats financiers pour le premier trimestre 2024 le 7 mai 2024. La société organisera une conférence téléphonique pour les investisseurs afin de discuter des résultats et de fournir des informations sur sa technologie d'ablation par champs pulsés nanosecondaires CellFX® (nsPFA™).
Pulse Biosciences, Inc. (PLSE) kündigte an, dass es seine Finanzergebnisse für das erste Quartal 2024 am 7. Mai 2024 veröffentlichen wird. Das Unternehmen wird einen Telefonkonferenz für Investoren veranstalten, um die Ergebnisse zu diskutieren und Einblicke in seine CellFX® Nanosekunden-Pulsfeldablationstechnologie (nsPFA™) zu geben.
Positive
None.
Negative
None.
HAYWARD, Calif.--(BUSINESS WIRE)--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.
Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
